AR050903A1 - Metodo para la prevencion de trastornos tromboticos, embolicos y/o hemorragicos - Google Patents
Metodo para la prevencion de trastornos tromboticos, embolicos y/o hemorragicosInfo
- Publication number
- AR050903A1 AR050903A1 ARP050101922A ARP050101922A AR050903A1 AR 050903 A1 AR050903 A1 AR 050903A1 AR P050101922 A ARP050101922 A AR P050101922A AR P050101922 A ARP050101922 A AR P050101922A AR 050903 A1 AR050903 A1 AR 050903A1
- Authority
- AR
- Argentina
- Prior art keywords
- embolic
- thrombotic
- prevention
- disorders
- hemorragical
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/50—Pyridazines; Hydrogenated pyridazines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/08—Vasodilators for multiple indications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Landscapes
- Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Epidemiology (AREA)
- Neurosurgery (AREA)
- Urology & Nephrology (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Hematology (AREA)
- Diabetes (AREA)
- Vascular Medicine (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
Un método para la prevencion o el tratamiento de trastornos tromboticos, embolicos y/o hemorrágicos, tales como el infarto cerebral (accidente cerebrovascular) o el infarto de miocardio, mediante la administracion de levosimendan o su metabolito (1) o cualquiera de sus sales adecuadas para uso farmacéutico, a un mamífero que requiera dicho tratamiento. Reivindicacion 1: Uso de levosimendan o su metabolito (II), o de cualquiera de sus sales adecuadas para uso farmacéutico, caracterizado porque es en la fabricacion de un medicamento para la prevencion o tratamiento de trastornos tromboticos, embolicos y/o hemorrágicos.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
FI20040674A FI20040674A0 (fi) | 2004-05-12 | 2004-05-12 | Menetelmä tromboembolisten sairauksien estoon |
Publications (1)
Publication Number | Publication Date |
---|---|
AR050903A1 true AR050903A1 (es) | 2006-12-06 |
Family
ID=32338383
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ARP050101922A AR050903A1 (es) | 2004-05-12 | 2005-05-11 | Metodo para la prevencion de trastornos tromboticos, embolicos y/o hemorragicos |
Country Status (16)
Country | Link |
---|---|
US (2) | US8017609B2 (es) |
EP (1) | EP1744752A2 (es) |
JP (1) | JP5074923B2 (es) |
KR (1) | KR20080020930A (es) |
CN (1) | CN1980673B (es) |
AR (1) | AR050903A1 (es) |
AU (1) | AU2005239847B2 (es) |
CA (1) | CA2564033A1 (es) |
EA (1) | EA010890B1 (es) |
FI (1) | FI20040674A0 (es) |
HK (1) | HK1107000A1 (es) |
NO (1) | NO20065669L (es) |
NZ (3) | NZ579537A (es) |
TW (1) | TWI366463B (es) |
WO (1) | WO2005107757A2 (es) |
ZA (1) | ZA200609304B (es) |
Families Citing this family (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
FI20040674A0 (fi) * | 2004-05-12 | 2004-05-12 | Orion Corp | Menetelmä tromboembolisten sairauksien estoon |
WO2006087420A2 (en) * | 2005-02-18 | 2006-08-24 | Orion Corporation | A method for treating heart failure |
JP2010514778A (ja) * | 2006-12-28 | 2010-05-06 | オリオン コーポレーション | 非経口投与のためのレボシメンダン製剤 |
TW200920371A (en) | 2007-08-29 | 2009-05-16 | Orion Corp | A combination treatment |
WO2010097501A2 (en) * | 2009-02-26 | 2010-09-02 | Orion Corporation | A combination treatment |
WO2011027021A1 (en) | 2009-09-01 | 2011-03-10 | Orion Corporation | A method for the treatment of hypertension |
EP2322163A1 (en) * | 2009-11-03 | 2011-05-18 | Pharnext | New therapeutics approaches for treating alzheimer disease |
KR101910153B1 (ko) * | 2016-11-04 | 2018-10-19 | 한국과학기술연구원 | 타우 관련 질환의 예방 또는 치료용 레보시멘단 화합물 |
WO2019216589A1 (ko) * | 2018-05-09 | 2019-11-14 | 한국과학기술연구원 | 타우 관련 질환의 예방 또는 치료용 조성물 |
CA3161960A1 (en) | 2019-12-16 | 2021-06-24 | Tenax Therapeutics, Inc. | Levosimendan for treating pulmonary hypertension with heart failure with preserved ejection fraction (ph-hfpef) |
CN115518037A (zh) * | 2022-10-14 | 2022-12-27 | 上药东英(江苏)药业有限公司 | 一种安全质量稳定的左西孟旦注射剂组合物及其制备方法 |
Family Cites Families (20)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB1468111A (en) * | 1976-01-08 | 1977-03-23 | Pfizer Ltd | Thiophene-sulphonamides |
DE3209159A1 (de) * | 1982-03-13 | 1983-09-15 | Basf Ag, 6700 Ludwigshafen | Neue 6-aryl-4,5-dihydro-3(2h)-pyridazinone, verfahren zu ihrer herstellung, diese verbindungen enthaltende therapeutische mittel und deren verwendung |
JPS63141970A (ja) * | 1986-12-04 | 1988-06-14 | Morishita Seiyaku Kk | 4,5−ジヒドロ−6−(4−置換フエニル)−3(2h)−ピリダジノン誘導体 |
GB2251615B (en) | 1991-01-03 | 1995-02-08 | Orion Yhtymae Oy | (-)-[[4-(1,4,5,6-tetrahydro-4-methyl-6-oxo-3-pyridazinyl)phenyl]hydrazono]pro panedinitrile |
GB2266841A (en) * | 1992-05-06 | 1993-11-17 | Orion Yhtymae Oy | Compounds for use as anti-ischemic medicaments |
US5945432A (en) * | 1995-12-22 | 1999-08-31 | The University Of Vermont And State Agricultural College | Thrombolytic agents and thienopyridine derivatives in acute stroke |
EP1008348A4 (en) * | 1997-02-27 | 2001-04-04 | Ajinomoto Kk | THROMBOLYTIC AGENT |
FI974578A (fi) * | 1997-12-19 | 1999-06-20 | Orion Yhtymae Oyj | Menetelmä levosimendaanin antamiseksi |
US5905078A (en) | 1998-06-19 | 1999-05-18 | Orion Corporation | Use of a pyridazinone derivative |
FI20001542A (fi) * | 2000-06-29 | 2001-12-30 | Orion Yhtymae Oyj | Menetelmä septisen sokin hoitamiseksi |
FI20011464A0 (fi) * | 2001-07-04 | 2001-07-04 | Orion Corp | Yhdistelmäterapia sydämen vajaatoiminnan hoitoon |
FI20011465A0 (fi) | 2001-07-04 | 2001-07-04 | Orion Corp | Pyridatsinonijohdannaisen uusi käyttö |
PT1430045E (pt) * | 2001-09-21 | 2007-01-31 | Novartis Ag | Derivados de pirano como inibidores de ace e nep |
FI20020197A0 (fi) | 2002-02-01 | 2002-02-01 | Orion Corp | Yhdistelmä akuutin myokardiilisen infarktin hoitoon |
FI20030015A0 (fi) * | 2003-01-03 | 2003-01-03 | Orion Corp | Menetelmä munuaisten vajaatoiminnan hoitamiseksi |
EP1579862A1 (en) | 2004-03-25 | 2005-09-28 | Boehringer Ingelheim Vetmedica Gmbh | Use of PDE III inhibitors for the reduction of heart size in mammals suffering from heart failure |
FI20040674A0 (fi) * | 2004-05-12 | 2004-05-12 | Orion Corp | Menetelmä tromboembolisten sairauksien estoon |
CN101031302A (zh) * | 2004-05-28 | 2007-09-05 | 艾博特公司 | 用于治疗心脏停搏前、期间和之后的哺乳动物的方法 |
WO2006087420A2 (en) * | 2005-02-18 | 2006-08-24 | Orion Corporation | A method for treating heart failure |
DK1951227T3 (en) | 2005-11-14 | 2017-07-10 | Boehringer Ingelheim Vetmedica Gmbh | APPLICATION OF PIMOBENDAN TO TREAT ASYMPTOMATIC (OCCULT) HEART FAILURE |
-
2004
- 2004-05-12 FI FI20040674A patent/FI20040674A0/fi not_active Application Discontinuation
-
2005
- 2005-04-28 TW TW094113669A patent/TWI366463B/zh not_active IP Right Cessation
- 2005-05-11 AR ARP050101922A patent/AR050903A1/es not_active Application Discontinuation
- 2005-05-12 NZ NZ579537A patent/NZ579537A/en not_active IP Right Cessation
- 2005-05-12 KR KR1020067023504A patent/KR20080020930A/ko not_active Application Discontinuation
- 2005-05-12 CN CN2005800142213A patent/CN1980673B/zh not_active Expired - Fee Related
- 2005-05-12 AU AU2005239847A patent/AU2005239847B2/en not_active Ceased
- 2005-05-12 WO PCT/FI2005/000220 patent/WO2005107757A2/en active Application Filing
- 2005-05-12 JP JP2007512237A patent/JP5074923B2/ja not_active Expired - Fee Related
- 2005-05-12 EP EP05739367A patent/EP1744752A2/en not_active Withdrawn
- 2005-05-12 NZ NZ579536A patent/NZ579536A/en not_active IP Right Cessation
- 2005-05-12 US US11/596,064 patent/US8017609B2/en not_active Expired - Fee Related
- 2005-05-12 CA CA002564033A patent/CA2564033A1/en not_active Abandoned
- 2005-05-12 EA EA200602096A patent/EA010890B1/ru not_active IP Right Cessation
- 2005-05-12 NZ NZ550814A patent/NZ550814A/en not_active IP Right Cessation
-
2006
- 2006-11-08 ZA ZA200609304A patent/ZA200609304B/en unknown
- 2006-12-08 NO NO20065669A patent/NO20065669L/no not_active Application Discontinuation
-
2007
- 2007-11-15 HK HK07112472.5A patent/HK1107000A1/xx not_active IP Right Cessation
-
2011
- 2011-08-11 US US13/207,537 patent/US8329693B2/en not_active Expired - Fee Related
Also Published As
Publication number | Publication date |
---|---|
JP2007537209A (ja) | 2007-12-20 |
FI20040674A0 (fi) | 2004-05-12 |
EA010890B1 (ru) | 2008-12-30 |
CA2564033A1 (en) | 2005-11-17 |
EA200602096A1 (ru) | 2007-04-27 |
NO20065669L (no) | 2006-12-08 |
ZA200609304B (en) | 2008-01-30 |
WO2005107757A3 (en) | 2006-01-19 |
AU2005239847B2 (en) | 2010-08-26 |
HK1107000A1 (en) | 2008-03-28 |
US8017609B2 (en) | 2011-09-13 |
JP5074923B2 (ja) | 2012-11-14 |
CN1980673B (zh) | 2011-11-23 |
US20110301166A1 (en) | 2011-12-08 |
AU2005239847A1 (en) | 2005-11-17 |
TWI366463B (en) | 2012-06-21 |
NZ550814A (en) | 2009-10-30 |
CN1980673A (zh) | 2007-06-13 |
US20080039467A1 (en) | 2008-02-14 |
KR20080020930A (ko) | 2008-03-06 |
TW200536546A (en) | 2005-11-16 |
EP1744752A2 (en) | 2007-01-24 |
NZ579536A (en) | 2011-03-31 |
WO2005107757A2 (en) | 2005-11-17 |
NZ579537A (en) | 2010-05-28 |
US8329693B2 (en) | 2012-12-11 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AR050903A1 (es) | Metodo para la prevencion de trastornos tromboticos, embolicos y/o hemorragicos | |
BR112016009889A2 (pt) | ?compostos agonistas duplos gip-glp-1 e métodos? | |
CL2011002206A1 (es) | Compuestos derivados de benzofurano sustituidos, moduladores del señalador igf1 o activador de la proteina quinasa b; composicion farmaceutica que los comprende; utiles en el tratamiento de enfermedades del snc, tales como alzheimer, entre otras. | |
CL2007001731A1 (es) | Compuestos derivados de imidazo[1,5-a]pirimidina; composicion farmaceutica; y uso para tratar o prevenir un trastorno asociado con el deterioro cognitivo, la enfermedad de alzheimer, demencia senil y demencia asociada con enfermedad de parkinson entre otras. | |
ECSP067021A (es) | Compuestos y composiciones como moduladores del receptor activado por proliferador de peroxisoma (ppar) | |
CL2007001732A1 (es) | Compuestos derivados de imidazo[1,5-a]pirimidina; composicion farmaceutica; y uso para tratar o prevenir un trastorno asociado con el deterioro cognitivo, la enfermedad de alzheimer, demencia senil y demencia asociada con enfermedad de parkinson entre otras. | |
CL2007001166A1 (es) | Compuestos derivados de pirimidina condensada, inhibidores de pi3-quinasa; procesos para preparar los compuestos; composicion farmaceutica que los comprende; uso de los compuestos en la preparacion de medicamentos; proceso para preparar la composicion farmaceutica; y kit que incluye a la composicion farmaceutica | |
CL2012002497A1 (es) | Compuestos derivados de imidazopirimidina,sustituidos, inhibidores de la pde10a; procedimiento de preparacion; composicion farmaceutica; y su uso para el tratamiento o prevencion de trastornos psicoticos, esquizofrenia, enfermedad de parkinson, esclerosis multiple, entre otras. | |
PA8770101A1 (es) | Amidas de 4-aril-1,4-dihidro-1, 6-naftiridina sustituidas y su uso | |
ECSP066559A (es) | ||
CL2010001159A1 (es) | Compuestos derivados de 3,8-diazabiciclo[2.4.0]octano y 3,6-diazabiciclo[3.2.0]heptano disustituidos, moduladores del receptor de orexina; composicion farmaceutica; utiles en el tratamiento de trastornos del sueño, trastornos metabolicos, entre otros. | |
CL2011001760A1 (es) | Combinación que comprende metotrexato y un inhibidor de dhodh no hepatotóxico; y uso en el tratamiento de enfermedades tales como artritis psoriatica, esclerosis multiple, psoriasis, entre otras. | |
ECSP088504A (es) | Uso de flibanserina para el tratamiento de trastornos del deseo sexual premenopáusicos | |
AR091876A1 (es) | Combinaciones farmaceuticas para el tratamiento de enfermedades proliferativas | |
ES2531516T3 (es) | Uso de escina | |
CO6382089A2 (es) | Compuestos,composiciones y metodos para el tratamiento de enfermadades causadas por un b-amiloide y sinucleinopatias | |
CL2014000246A1 (es) | Compuestos derivados fenil-3-aza-biciclo[3.1.0]hex-3-il-metanonas, inhibidores del transportador de glicina (glyt1); composicion farmaceutica que los contiene; combinacion farmaceutica; y su uso en el tratamiento de alzheimer, alteraciones cognitivas en esquizofrenia, psicosis, trastornos psiquiatricos, entre otros | |
CL2008000981A1 (es) | Compuestos derivados de imidazolidin-carboxamida; composicion farmaceutica; procedimiento de produccion de la composicion farmaceutica; y uso en el tratamiento y/o prevencion de trastornos ateroscleroticos, de metabolismo de acidos grasos y en los qu | |
BR112014005025A2 (pt) | composição farmacêutica para uso no tratamento de uma doença neurodegenerativa | |
CL2013002394A1 (es) | Compuestos derivados de 6,7-dialcoxi-3-isoquinolinol sustituidos, inhibidores de la pde10a; composicion farmaceutica que los comprende; y su uso en el tratamiento de trastornos metabolicos, trastornos del snc tales como enfermedad de alzheimer, demencia, depresion y trastornos neurodegenerativos tales como esclerosis multiple, entre otros. | |
CO2017012622A2 (es) | Moduladores alostéricos positivos del receptor muscarínico m2 | |
GT200500266A (es) | Nuevos derivados de pirimidina y su uso | |
ECSP088366A (es) | 1,2-diarilimidazoles para uso como moduladores de cb1 | |
PE20151664A1 (es) | Un polipeptido receptor del factor de crecimiento de fibroblasto soluble 3 (fgr3) para el uso en la prevencion o tratamiento de trastornos de retraso de crecimiento esqueletico | |
AR094241A1 (es) | Ciclesonida para el tratamiento de la enfermedad de las vias respiratorias en caballos |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FA | Abandonment or withdrawal |